Regulation of the thioredoxin-dependent system as an element of pharmacotherapy in redox-impaired diseases

[1] Ahsan M.K., Lekli I., Ray D., Yodoi J., Das D.K.: Redox regulation of cell survival by the thioredoxin superfamily: An implication of redox gene therapy in the heart. Antioxid. Redox Signal., 2009; 11: 2741–2758 AhsanM.K. LekliI. RayD. YodoiJ. DasD.K. Redox regulation of cell survival by the thioredoxin superfamily: An implication of redox gene therapy in the heart Antioxid. Redox Signal. 2009 11 2741 2758 10.1089/ars.2009.2683282113419583492 Search in Google Scholar

[2] An N., Kang Y.: Thioredoxin and hematologic malignancies. W: Advances in Cancer Research, t. 122, red.: D.M. Townsend, K.D. Tew. Academic Press, London, 2014, 245–279 AnN. KangY. Thioredoxin and hematologic malignancies W: Advances in Cancer Research 122 red.: TownsendD.M. TewK.D. Academic Press London 2014 245 279 10.1016/B978-0-12-420117-0.00007-424974184 Search in Google Scholar

[3] Arnér E.S.: Focus on mammalian thioredoxin reductases – important selenoproteins with versatile functions. Biochim. Biophys. Acta, 2009; 1790: 495–526 ArnérE.S. Focus on mammalian thioredoxin reductases – important selenoproteins with versatile functions Biochim. Biophys. Acta 2009 1790 495 526 10.1016/j.bbagen.2009.01.01419364476 Search in Google Scholar

[4] Arnér E.S.: Selenocysteine insertion and reactivity: Mammalian thioredoxin reductases in relation to cellular redox signaling. W: Cellular Implications of Redox Signaling, red.: C. Gitler, A. Danon. Imperial College Press, London 2003, 27–45 ArnérE.S. Selenocysteine insertion and reactivity: Mammalian thioredoxin reductases in relation to cellular redox signaling W: Cellular Implications of Redox Signaling red.: GitlerC. DanonA. Imperial College Press London 2003 27 45 10.1142/9781848160033_0002 Search in Google Scholar

[5] Avval F.Z., Holmgren A.: Molecular mechanisms of thioredoxin and glutaredoxin as hydrogen donors for Mammalian s phase ribonucleotide reductase. J. Biol. Chem., 2009; 284: 8233–8240 AvvalF.Z. HolmgrenA. Molecular mechanisms of thioredoxin and glutaredoxin as hydrogen donors for Mammalian s phase ribonucleotide reductase J. Biol. Chem. 2009 284 8233 8240 10.1074/jbc.M809338200265918019176520 Search in Google Scholar

[6] Baker A.F., Adab K.N., Raghunand N., Chow H., Stratton S.P., Squire S.W., Boice M., Pestano L.A., Kirkpatrick D.L., Dragovich T.: A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers. Invest. New Drugs, 2013; 31: 631–641 BakerA.F. AdabK.N. RaghunandN. ChowH. StrattonS.P. SquireS.W. BoiceM. PestanoL.A. KirkpatrickD.L. DragovichT. A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers Invest. New Drugs 2013 31 631 641 10.1007/s10637-012-9846-2398898122711542 Search in Google Scholar

[7] Baker A.F., Dragovich T., Tate W.R., Ramanathan R.K., Roe D., Hsu C.H., Kirkpatrick D.L., Powis G.: The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. J. Lab. Clin. Med., 2006; 147: 83–90 BakerA.F. DragovichT. TateW.R. RamanathanR.K. RoeD. HsuC.H. KirkpatrickD.L. PowisG. The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma J. Lab. Clin. Med. 2006 147 83 90 10.1016/j.lab.2005.09.001143209116459166 Search in Google Scholar

[8] Berdicevsky I., Kaufman G., Newman D.J., Horwitz B.A.: Preliminary study of activity of the thioredoxin inhibitor pleurotin against Trichophyton mentagrophytes: A novel anti-dermatophyte possibility. Mycoses, 2009; 52: 313–317 BerdicevskyI. KaufmanG. NewmanD.J. HorwitzB.A. Preliminary study of activity of the thioredoxin inhibitor pleurotin against Trichophyton mentagrophytes: A novel anti-dermatophyte possibility Mycoses 2009 52 313 317 10.1111/j.1439-0507.2008.01620.x18793260 Search in Google Scholar

[9] Berndt C., Lillig C.H., Holmgren A.: Thioredoxins and glutaredoxins as facilitators of protein folding. Biochim. Biophys. Acta, 2008; 1783: 641–650 BerndtC. LilligC.H. HolmgrenA. Thioredoxins and glutaredoxins as facilitators of protein folding Biochim. Biophys. Acta 2008 1783 641 650 10.1016/j.bbamcr.2008.02.00318331844 Search in Google Scholar

[10] Bignon E., Allega M.F., Lucchetta M., Tiberti M., Papaleo E.: Computational structural biology of S-nitrosylation of cancer targets. Front. Oncol., 2018; 8: 272 BignonE. AllegaM.F. LucchettaM. TibertiM. PapaleoE. Computational structural biology of S-nitrosylation of cancer targets Front. Oncol. 2018 8 272 10.3389/fonc.2018.00272610237130155439 Search in Google Scholar

[11] Bilska A., Kryczyk A., Włodek L.: Różne oblicza biologicznej roli glutationu. Postępy Hig. Med. Dośw., 2007; 61: 438–453 BilskaA. KryczykA. WłodekL. Różne oblicza biologicznej roli glutationu Postępy Hig. Med. Dośw. 2007 61 438 453 Search in Google Scholar

[12] Brandstaedter C., Fritz-Wolf K., Weder S., Fischer M., Hecker B., Rahlfs S., Becker K.: Kinetic characterization of wild-type and mutant human thioredoxin glutathione reductase defines its reaction and regulatory mechanisms., FEBS J., 2018; 285; 542–558 BrandstaedterC. Fritz-WolfK. WederS. FischerM. HeckerB. RahlfsS. BeckerK. Kinetic characterization of wild-type and mutant human thioredoxin glutathione reductase defines its reaction and regulatory mechanisms FEBS J. 2018 285 542 558 10.1111/febs.1435729222842 Search in Google Scholar

[13] Cai W., Zhang B., Duan D., Wu J., Fang J.: Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells. Toxicol. Appl. Pharmacol., 2012; 262: 341–348 CaiW. ZhangB. DuanD. WuJ. FangJ. Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells Toxicol. Appl. Pharmacol. 2012 262 341 348 10.1016/j.taap.2012.05.01222634334 Search in Google Scholar

[14] Chen X., Tang W., Liu S., Yu L., Chen Z.: Thioredoxin-1 phosphorylated at T100 is needed for its anti-apoptotic activity in HepG2 cancer cells. Life Sci., 2010; 87, 254–260 ChenX. TangW. LiuS. YuL. ChenZ. Thioredoxin-1 phosphorylated at T100 is needed for its anti-apoptotic activity in HepG2 cancer cells Life Sci. 2010 87 254 260 10.1016/j.lfs.2010.06.01820619274 Search in Google Scholar

[15] Chondrogianni N., Petropoulos I., Grimm S., Georgila K., Catalgol B., Friguet B., Grune T., Gonos, E.S.: Protein damage, repair and proteolysis. Mol. Aspects Med., 2014; 35: 1–71 ChondrogianniN. PetropoulosI. GrimmS. GeorgilaK. CatalgolB. FriguetB. GruneT. GonosE.S. Protein damage, repair and proteolysis Mol. Aspects Med. 2014 35 1 71 10.1016/j.mam.2012.09.00123107776 Search in Google Scholar

[16] Circu M.L., Aw T.Y.: Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med., 2010; 48: 749–762 CircuM.L. AwT.Y. Reactive oxygen species, cellular redox systems, and apoptosis Free Radic. Biol. Med. 2010 48 749 762 10.1016/j.freeradbiomed.2009.12.022282397720045723 Search in Google Scholar

[17] Citta A., Folda A., Scutari G., Cesaro L., Bindoli A., Rigobello, M.P.: Inhibition of thiore8doxin reductase by lanthanum chloride. J. Inorg. Biochem., 2012; 117: 18–24 CittaA. FoldaA. ScutariG. CesaroL. BindoliA. RigobelloM.P. Inhibition of thiore8doxin reductase by lanthanum chloride J. Inorg. Biochem. 2012 117 18 24 10.1016/j.jinorgbio.2012.08.01423078771 Search in Google Scholar

[18] Collet J.F., Messens J.: Structure, function, and mechanism of thioredoxin proteins. Antioxid. Redox Signal., 2010; 13: 1205–1216 ColletJ.F. MessensJ. Structure, function, and mechanism of thioredoxin proteins Antioxid. Redox Signal. 2010 13 1205 1216 10.1089/ars.2010.311420136512 Search in Google Scholar

[19] Cortes-Bratti X., Bassères E., Herrera-Rodriguez F., Botero-Kleiven S., Coppotelli G., Andersen J.B., Masucci M.G., Holmgren A., Chaves-Olarte E., Frisan T., Avila-Carino J.: Thioredoxin 80-activated-monocytes (TAMs) inhibit the replication of intracellular pathogens. PLoS One, 2011; 6: e16960 Cortes-BrattiX. BassèresE. Herrera-RodriguezF. Botero-KleivenS. CoppotelliG. AndersenJ.B. MasucciM.G. HolmgrenA. Chaves-OlarteE. FrisanT. Avila-CarinoJ. Thioredoxin 80-activated-monocytes (TAMs) inhibit the replication of intracellular pathogens PLoS One 2011 6 e16960 10.1371/journal.pone.0016960304181921365006 Search in Google Scholar

[20] Cutillas N., Yellol G.S., de Haro C., Vicente C., Rodríguez V., Ruiz J.: Anticancer cyclometalated complexes of platinum group metals and gold. Coord. Chem. Rev., 2013; 257: 2784–2791 CutillasN. YellolG.S. de HaroC. VicenteC. RodríguezV. RuizJ. Anticancer cyclometalated complexes of platinum group metals and gold Coord. Chem. Rev. 2013 257 2784 2791 10.1016/j.ccr.2013.03.024 Search in Google Scholar

[21] de Oliveira K.N., Andermark V., Onambele L.A., Dahl G., Prokop A., Ott, I.: Organotin complexes containing carboxylate ligands with maleimide and naphthalimide derived partial structures: TrxR inhibition, cytotoxicity and activity in resistant cancer cells. Eur. J. Med. Chem., 2014; 87: 794–800 de OliveiraK.N. AndermarkV. OnambeleL.A. DahlG. ProkopA. OttI. Organotin complexes containing carboxylate ligands with maleimide and naphthalimide derived partial structures: TrxR inhibition, cytotoxicity and activity in resistant cancer cells Eur. J. Med. Chem. 2014 87 794 800 10.1016/j.ejmech.2014.09.07525440880 Search in Google Scholar

[22] Dmitrenko O., Orlova T., Terenetskaya I.: Medium controlled photochemistry of provitamin D: From solutions to liquid crystals. J. Mol. Liq., 2018; 267: 428–435 DmitrenkoO. OrlovaT. TerenetskayaI. Medium controlled photochemistry of provitamin D: From solutions to liquid crystals J. Mol. Liq. 2018 267 428 435 10.1016/j.molliq.2018.01.049 Search in Google Scholar

[23] Dobrovolska O., Rychkov G., Shumilina E., Nerinovski K., Schmidt A., Shabalin K., Yakimov A., Dikiy A.: Structural insights into interaction between mammalian methionine sulfoxide reductase B1 and thioredoxin. J. Biomed. Biotechnol., 2012; 2012: 586539 DobrovolskaO. RychkovG. ShumilinaE. NerinovskiK. SchmidtA. ShabalinK. YakimovA. DikiyA. Structural insights into interaction between mammalian methionine sulfoxide reductase B1 and thioredoxin J. Biomed. Biotechnol. 2012 2012 586539 10.1155/2012/586539331229622505815 Search in Google Scholar

[24] Dóka É., Pader I., Bíró A., Johansson K., Cheng Q., Ballagó K., Prigge J.R., Pastor-Flores D., Dick T.P., Schmidt E.E., Arnér E.S., Nagy P.: A novel persulfide detection method reveals protein persulfideand polysulfide-reducing functions of thioredoxin and glutathione systems. Sci. Adv., 2016; 2: e1500968 DókaÉ. PaderI. BíróA. JohanssonK. ChengQ. BallagóK. PriggeJ.R. Pastor-FloresD. DickT.P. SchmidtE.E. ArnérE.S. NagyP. A novel persulfide detection method reveals protein persulfideand polysulfide-reducing functions of thioredoxin and glutathione systems Sci. Adv. 2016 2 e1500968 10.1126/sciadv.1500968473720826844296 Search in Google Scholar

[25] Ellgaard L. Ruddock L.W.: The human protein disulphide isomerase family: Substrate interactions and functional properties. EMBO Rep., 2005; 6: 28–32 EllgaardL. RuddockL.W. The human protein disulphide isomerase family: Substrate interactions and functional properties EMBO Rep. 2005 6 28 32 10.1038/sj.embor.7400311129922115643448 Search in Google Scholar

[26] Fang J., Holmgren A.: Inhibition of thioredoxin and thioredoxin reductase by 4-hydroxy-2-nonenal in vitro and in vivo. J. Am. Chem. Soc., 2006; 128: 1879–1885 FangJ. HolmgrenA. Inhibition of thioredoxin and thioredoxin reductase by 4-hydroxy-2-nonenal in vitro and in vivo J. Am. Chem. Soc. 2006 128 1879 1885 10.1021/ja057358l16464088 Search in Google Scholar

[27] Fujiwara N., Fujii T., Fujii J., Taniguchi N.: Roles of N-terminal active cysteines and C-terminal cysteine-selenocysteine in the catalytic mechanism of mammalian thioredoxin reductase. J. Biochem., 2001; 129: 803–812 FujiwaraN. FujiiT. FujiiJ. TaniguchiN. Roles of N-terminal active cysteines and C-terminal cysteine-selenocysteine in the catalytic mechanism of mammalian thioredoxin reductase J. Biochem. 2001 129 803 812 10.1093/oxfordjournals.jbchem.a00292311328605 Search in Google Scholar

[28] Galligan J.J., Petersen D.R.: The human protein disulfide isomerase gene family. Hum. Genomics, 2012; 6: 6 GalliganJ.J. PetersenD.R. The human protein disulfide isomerase gene family Hum. Genomics 2012 6 6 10.1186/1479-7364-6-6350022623245351 Search in Google Scholar

[29] Gandin V., Fernandes A.P.: Metal-and semimetal-containing inhibitors of thioredoxin reductase as anticancer agents. Molecules, 2015; 20: 12732–12756 GandinV. FernandesA.P. Metal-and semimetal-containing inhibitors of thioredoxin reductase as anticancer agents Molecules 2015 20 12732 12756 10.3390/molecules200712732633189526184149 Search in Google Scholar

[30] Gaschler M.M., Stockwell B.R.: Lipid peroxidation in cell death. Biochem. Biophys. Res. Commun., 2017; 482: 419–425 GaschlerM.M. StockwellB.R. Lipid peroxidation in cell death Biochem. Biophys. Res. Commun. 2017 482 419 425 10.1016/j.bbrc.2016.10.086531940328212725 Search in Google Scholar

[31] Ghezzi P.: Protein glutathionylation in health and disease. Biochim. Biophys. Acta, 2013; 1830: 3165–3172 GhezziP. Protein glutathionylation in health and disease Biochim. Biophys. Acta 2013 1830 3165 3172 10.1016/j.bbagen.2013.02.00923416063 Search in Google Scholar

[32] Gil-Bea F., Akterin S., Persson T., Mateos L., Sandebring A., Avila-Cariño J., Gutierrez-Rodriguez A., Sundström E., Holmgren A., Winblad B., Cedazo-Minguez A.: Thioredoxin-80 is a product of alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in Alzheimer’s disease brain. EMBO Mol. Med., 2012; 4: 1097–1111 Gil-BeaF. AkterinS. PerssonT. MateosL. SandebringA. Avila-CariñoJ. Gutierrez-RodriguezA. SundströmE. HolmgrenA. WinbladB. Cedazo-MinguezA. Thioredoxin-80 is a product of alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in Alzheimer’s disease brain EMBO Mol. Med. 2012 4 1097 1111 10.1002/emmm.201201462349183922933306 Search in Google Scholar

[33] Goroncy A.K., Koshiba S., Tochio N., Tomizawa T., Inoue M., Tanaka A., Sugano S., Kigawa T., Yokoyama S.: Solution structure of the C-terminal DUF1000 domain of the human thioredoxin-like 1 protein. Proteins, 2010; 78: 2176–2180 GoroncyA.K. KoshibaS. TochioN. TomizawaT. InoueM. TanakaA. SuganoS. KigawaT. YokoyamaS. Solution structure of the C-terminal DUF1000 domain of the human thioredoxin-like 1 protein Proteins 2010 78 2176 2180 10.1002/prot.2271920455272 Search in Google Scholar

[34] Gromer S., Urig S., Becker K.: The thioredoxin system – from science to clinic. Med. Res. Rev., 2004; 24: 40–89 GromerS. UrigS. BeckerK. The thioredoxin system – from science to clinic Med. Res. Rev. 2004 24 40 89 10.1002/med.1005114595672 Search in Google Scholar

[35] Hashemy S.I., Ungerstedt J.S., Avval F.Z., Holmgren A.: Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J. Biol. Chem., 2006; 281: 10691–10697 HashemyS.I. UngerstedtJ.S. AvvalF.Z. HolmgrenA. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase J. Biol. Chem. 2006 281 10691 10697 10.1074/jbc.M51137320016481328 Search in Google Scholar

[36] Hatahet F., Ruddock L.W.: Protein disulfide isomerase: A critical evaluation of its function in disulfide bond formation. Antioxid. Redox Signal., 2009; 11: 2807–2850 HatahetF. RuddockL.W. Protein disulfide isomerase: A critical evaluation of its function in disulfide bond formation Antioxid. Redox Signal. 2009 11 2807 2850 10.1089/ars.2009.246619476414 Search in Google Scholar

[37] Hickey J.L., Ruhayel R.A., Barnard P.J., Baker M.V., Berners-Price S.J., Filipovska A.: Mitochondria-targeted chemotherapeutics: The rational design of gold (I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. J. Am. Chem. Soc., 2008; 130: 12570–12571 HickeyJ.L. RuhayelR.A. BarnardP.J. BakerM.V. Berners-PriceS.J. FilipovskaA. Mitochondria-targeted chemotherapeutics: The rational design of gold (I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols J. Am. Chem. Soc. 2008 130 12570 12571 10.1021/ja804027j18729360 Search in Google Scholar

[38] Holmgren A., Lu J.: Thioredoxin and thioredoxin reductase: Current research with special reference to human disease. Biochem. Biophys. Res. Commun., 2010; 396: 120–124 HolmgrenA. LuJ. Thioredoxin and thioredoxin reductase: Current research with special reference to human disease Biochem. Biophys. Res. Commun. 2010 396 120 124 10.1016/j.bbrc.2010.03.08320494123 Search in Google Scholar

[39] Hruza L.L., Pentland A.P.: Mechanisms of UV–induced inflammation. J. Invest. Dermatol., 1993; 100: S35–S41 HruzaL.L. PentlandA.P. Mechanisms of UV–induced inflammation J. Invest. Dermatol. 1993 100 S35 S41 10.1038/jid.1993.21 Search in Google Scholar

[40] Ishii T., Funato Y., Miki H.: Thioredoxin-related protein 32 (TRP32) specifically reduces oxidized phosphatase of regenerating liver (PRL). J. Biol. Chem., 2013; 288: 7263–7270 IshiiT. FunatoY. MikiH. Thioredoxin-related protein 32 (TRP32) specifically reduces oxidized phosphatase of regenerating liver (PRL) J. Biol. Chem. 2013 288 7263 7270 10.1074/jbc.M112.418004359163423362275 Search in Google Scholar

[41] Jiménez A., Zu W., Rawe V.Y., Pelto-Huikko M., Flickinger C.J., Sutovsky P., Gustafsson J.Å. Oko R., Miranda-Vizuete A.: Spermatocyte/spermatid-specific thioredoxin-3, a novel Golgi apparatus-associated thioredoxin, is a specific marker of aberrant spermatogenesis. J. Biol. Chem., 2004; 279: 34971–34982 JiménezA. ZuW. RaweV.Y. Pelto-HuikkoM. FlickingerC.J. SutovskyP. GustafssonJ.Å. OkoR. Miranda-VizueteA. Spermatocyte/spermatid-specific thioredoxin-3, a novel Golgi apparatus-associated thioredoxin, is a specific marker of aberrant spermatogenesis J. Biol. Chem. 2004 279 34971 34982 10.1074/jbc.M40419220015181017 Search in Google Scholar

[42] Jones D.A.: Rosacea, reactive oxygen species, and azelaic acid. J. Clin. Aesthet. Dermatol., 2009; 2: 26–30 JonesD.A. Rosacea, reactive oxygen species, and azelaic acid J. Clin. Aesthet. Dermatol. 2009 2 26 30 Search in Google Scholar

[43] Ju Y., Wu L., Yang G.: Thioredoxin 1 regulation of protein S-desulfhydration. Biochem. Biophys. Rep., 2016; 5: 27–34 JuY. WuL. YangG. Thioredoxin 1 regulation of protein S-desulfhydration Biochem. Biophys. Rep. 2016 5 27 34 10.1016/j.bbrep.2015.11.012560046128955804 Search in Google Scholar

[44] Kakkar P., Singh B.K.: Mitochondria: A hub of redox activities and cellular distress control. Mol. Cell. Biochem., 2007; 305: 235–253 KakkarP. SinghB.K. Mitochondria: A hub of redox activities and cellular distress control Mol. Cell. Biochem. 2007 305 235 253 10.1007/s11010-007-9520-817562131 Search in Google Scholar

[45] Karlenius T.C., Tonissen, K.F.: Thioredoxin and cancer:A role for thioredoxin in all states of tumor oxygenation. Cancers, 2010; 2: 209–232 KarleniusT.C. TonissenK.F. Thioredoxin and cancer:A role for thioredoxin in all states of tumor oxygenation Cancers 2010 2 209 232 10.3390/cancers2020209383507624281068 Search in Google Scholar

[46] Korkina L.: Metabolic and redox barriers in the skin exposed to drugs and xenobiotics. Expert Opin. Drug Metab. Toxicol., 2016; 12: 377–388 KorkinaL. Metabolic and redox barriers in the skin exposed to drugs and xenobiotics Expert Opin. Drug Metab. Toxicol. 2016 12 377 388 10.1517/17425255.2016.114956926854731 Search in Google Scholar

[47] Lee S., Kim S.M., Lee R.T.: Thioredoxin and thioredoxin target proteins: From molecular mechanisms to functional significance. Antioxid. Redox Signal., 2013; 18: 1165–1207 LeeS. KimS.M. LeeR.T. Thioredoxin and thioredoxin target proteins: From molecular mechanisms to functional significance Antioxid. Redox Signal. 2013 18 1165 1207 10.1089/ars.2011.4322357938522607099 Search in Google Scholar

[48] Lehmann B., Meurer M.: Vitamin D metabolism. Dermatol. Ther., 2010; 23, 2–12 LehmannB. MeurerM. Vitamin D metabolism Dermatol. Ther. 2010 23 2 12 10.1111/j.1529-8019.2009.01286.x20136904 Search in Google Scholar

[49] Li G.Z., Liang H.F., Liao B., Zhang L., Ni Y.A., Zhou H.H., Zhang E.L., Zhang B.X., Chen X.P.: PX-12 inhibits the growth of hepatocelluar carcinoma by inducing S-phase arrest, ROS-dependent apoptosis and enhances 5-FU cytotoxicity. Am. J. Transl. Res., 2015; 7: 1528–1540 LiG.Z. LiangH.F. LiaoB. ZhangL. NiY.A. ZhouH.H. ZhangE.L. ZhangB.X. ChenX.P. PX-12 inhibits the growth of hepatocelluar carcinoma by inducing S-phase arrest, ROS-dependent apoptosis and enhances 5-FU cytotoxicity Am. J. Transl. Res. 2015 7 1528 1540 Search in Google Scholar

[50] Li H., Xu C., Li Q., Gao X., Sugano E., Tomita H., Yang L., Shi S.: Thioredoxin 2 offers protection against mitochondrial oxidative stress in H9c2 cells and against myocardial hypertrophy induced by hyperglycemia. Int. J. Mol. Sci., 2017; 18: 1958 LiH. XuC. LiQ. GaoX. SuganoE. TomitaH. YangL. ShiS. Thioredoxin 2 offers protection against mitochondrial oxidative stress in H9c2 cells and against myocardial hypertrophy induced by hyperglycemia Int. J. Mol. Sci. 2017 18 1958 10.3390/ijms18091958561860728914755 Search in Google Scholar

[51] Liao J., Wang K., Yao W., Yi X., Yan H., Chen M., Lan X.: Cloning, expression and antioxidant activity of a thioredoxin peroxidase from Branchiostoma belcheri tsingtaunese. PLoS One, 2017; 12: e0175162 LiaoJ. WangK. YaoW. YiX. YanH. ChenM. LanX. Cloning, expression and antioxidant activity of a thioredoxin peroxidase from Branchiostoma belcheri tsingtaunese PLoS One 2017 12 e0175162 10.1371/journal.pone.0175162538324728384204 Search in Google Scholar

[52] Lillig C.H., Holmgren A.: Thioredoxin and related molecules – from biology to health and disease. Antioxid. Redox Signal., 2007; 9: 25–47 LilligC.H. HolmgrenA. Thioredoxin and related molecules – from biology to health and disease Antioxid. Redox Signal. 2007 9 25 47 10.1089/ars.2007.9.2517115886 Search in Google Scholar

[53] Lu J., Papp L.V., Fang J., Rodriguez-Nieto S., Zhivotovsky B., Holmgren A.: Inhibition of mammalian thioredoxin reductase by some flavonoids: Implications for myricetin and quercetin anti-cancer activity. Cancer Res., 2006; 66: 4410–4418 LuJ. PappL.V. FangJ. Rodriguez-NietoS. ZhivotovskyB. HolmgrenA. Inhibition of mammalian thioredoxin reductase by some flavonoids: Implications for myricetin and quercetin anti-cancer activity Cancer Res. 2006 66 4410 4418 10.1158/0008-5472.CAN-05-331016618767 Search in Google Scholar

[54] Lu Y., Wang X., Liu Z., Jin B., Chu D., Zhai H., Zhang F., Li K., Ren G., Miranda-Vizuete A., Guo X., Fan D.: Identification and distribution of thioredoxin-like 2 as the antigen for the monoclonal antibody MC3 specific to colorectal cancer. Proteomics, 2008; 8: 2220–2229 LuY. WangX. LiuZ. JinB. ChuD. ZhaiH. ZhangF. LiK. RenG. Miranda-VizueteA. GuoX. FanD. Identification and distribution of thioredoxin-like 2 as the antigen for the monoclonal antibody MC3 specific to colorectal cancer Proteomics 2008 8 2220 2229 10.1002/pmic.20070077018528843 Search in Google Scholar

[55] Maillet A., Pervaiz S.: Redox regulation of p53, redox effectors regulated by p53: A subtle balance. Antioxid. Redox Signal., 2012; 16: 1285–1294 MailletA. PervaizS. Redox regulation of p53, redox effectors regulated by p53: A subtle balance Antioxid. Redox Signal. 2012 16 1285 1294 10.1089/ars.2011.443422117613 Search in Google Scholar

[56] Maulik N., Das D.K.: Emerging potential of thioredoxin and thioredoxin interacting proteins in various disease conditions. Biochim. Biophys. Acta, 2008; 1780: 1368–1382 MaulikN. DasD.K. Emerging potential of thioredoxin and thioredoxin interacting proteins in various disease conditions Biochim. Biophys. Acta 2008 1780 1368 1382 10.1016/j.bbagen.2007.12.00818206121 Search in Google Scholar

[57] Mukherjee A., Martin S.G.: The thioredoxin system: A key target in tumour and endothelial cells. Br. J. Radiol., 2008; 81: S57–S68 MukherjeeA. MartinS.G. The thioredoxin system: A key target in tumour and endothelial cells Br. J. Radiol. 2008 81 S57 S68 10.1259/bjr/3418043518819999 Search in Google Scholar

[58] Mura P., Camalli M., Bindoli A., Sorrentino F., Casini A., Gabbiani C., Corsini M., Zanello P., Rigobello M.P., Messori L.: Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis (2-amino-5-methylthiazole) tetrachlororuthenate (III)]: First report of relevant thioredoxin reductase inhibition for a ruthenium compound. J. Med. Chem., 2007; 50: 5871–5874 MuraP. CamalliM. BindoliA. SorrentinoF. CasiniA. GabbianiC. CorsiniM. ZanelloP. RigobelloM.P. MessoriL. Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis (2-amino-5-methylthiazole) tetrachlororuthenate (III)]: First report of relevant thioredoxin reductase inhibition for a ruthenium compound J. Med. Chem. 2007 50 5871 5874 10.1021/jm070857817975904 Search in Google Scholar

[59] Ng H.L., Chen S., Chew E.H., Chui W.K.: Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity. Eur. J. Med. Chem., 2016; 115: 63–74 NgH.L. ChenS. ChewE.H. ChuiW.K. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity Eur. J. Med. Chem. 2016 115 63 74 10.1016/j.ejmech.2016.03.00226994844 Search in Google Scholar

[60] Oehninger L., Küster L.N., Schmidt C., Muñoz-Castro A., Prokop A., Ott I.: A chemical-biological evaluation of rhodium (I) N-heterocyclic carbene complexes as prospective anticancer drugs. Chem. Eur. J., 2013; 19: 17871–17880 OehningerL. KüsterL.N. SchmidtC. Muñoz-CastroA. ProkopA. OttI. A chemical-biological evaluation of rhodium (I) N-heterocyclic carbene complexes as prospective anticancer drugs Chem. Eur. J. 2013 19 17871 17880 10.1002/chem.20130281924243420 Search in Google Scholar

[61] Oguro A., Imaoka S.: Thioredoxin-related transmembrane protein 2 (TMX2) regulates the Ran protein gradient and importin-β-dependent nuclear cargo transport. Sci. Rep., 2019; 9: 15296 OguroA. ImaokaS. Thioredoxin-related transmembrane protein 2 (TMX2) regulates the Ran protein gradient and importin-β-dependent nuclear cargo transport Sci. Rep. 2019 9 15296 10.1038/s41598-019-51773-x681478831653923 Search in Google Scholar

[62] Oka O.B., Bulleid N.J.: Forming disulfides in the endoplasmic reticulum. Biochim. Biophys. Acta, 2013; 1833: 2425–2429 OkaO.B. BulleidN.J. Forming disulfides in the endoplasmic reticulum Biochim. Biophys. Acta 2013 1833 2425 2429 10.1016/j.bbamcr.2013.02.00723434683 Search in Google Scholar

[63] Orlova T.N., Terenetskaya I.P.: Possible use of provitamin D3 photoisomerization for spectral dosimetry of bioactive antirachitic UV radiation. J. Appl. Spectrosc., 2009; 76, 240–244 OrlovaT.N. TerenetskayaI.P. Possible use of provitamin D3 photoisomerization for spectral dosimetry of bioactive antirachitic UV radiation J. Appl. Spectrosc. 2009 76 240 244 10.1007/s10812-009-9159-1 Search in Google Scholar

[64] Ortego L., Cardoso F., Martins S., Fillat M.F., Laguna A., Meireles M., Villacampa M.D., Gimeno M.C.: Strong inhibition of thioredoxin reductase by highly cytotoxic gold (I) complexes. DNA binding studies. J. Inorg. Biochem., 2014; 130: 32–37 OrtegoL. CardosoF. MartinsS. FillatM.F. LagunaA. MeirelesM. VillacampaM.D. GimenoM.C. Strong inhibition of thioredoxin reductase by highly cytotoxic gold (I) complexes. DNA binding studies J. Inorg. Biochem. 2014 130 32 37 10.1016/j.jinorgbio.2013.09.01924157605 Search in Google Scholar

[65] Palanisamy R., Bhatt P., Kumaresan V., Chaurasia M.K., Gnanam A.J., Pasupuleti M., Kasi M., Arockiaraj J.: A redox active site containing murrel cytosolic thioredoxin: Analysis of immunological properties. Fish Shellfish Immunol., 2014; 36: 141–150 PalanisamyR. BhattP. KumaresanV. ChaurasiaM.K. GnanamA.J. PasupuletiM. KasiM. ArockiarajJ. A redox active site containing murrel cytosolic thioredoxin: Analysis of immunological properties Fish Shellfish Immunol. 2014 36 141 150 10.1016/j.fsi.2013.10.01624516870 Search in Google Scholar

[66] Poet G.J., Oka O.B., van Lith M., Cao Z., Robinson P.J., Pringle M.A., Arnér E.S., Bulleid N.J.: Cytosolic thioredoxin reductase 1 is required for correct disulfide formation in the ER. EMBO J., 2017; 36: 693–702 PoetG.J. OkaO.B. van LithM. CaoZ. RobinsonP.J. PringleM.A. ArnérE.S. BulleidN.J. Cytosolic thioredoxin reductase 1 is required for correct disulfide formation in the ER EMBO J. 2017 36 693 702 10.15252/embj.201695336533176028093500 Search in Google Scholar

[67] Powis G., Wipf P., Lynch S.M., Birmingham A., Kirkpatrick D.L.: Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase. Mol. Cancer Ther., 2006; 5: 630–636 PowisG. WipfP. LynchS.M. BirminghamA. KirkpatrickD.L. Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase Mol. Cancer Ther. 2006 5 630 636 10.1158/1535-7163.MCT-05-0487146292516546977 Search in Google Scholar

[68] Prast-Nielsen S., Huang H.H., Williams, D.L.: Thioredoxin glutathione reductase: Its role in redox biology and potential as a target for drugs against neglected diseases. Biochim. Biophys. Acta, 2011; 1810: 1262–1271 Prast-NielsenS. HuangH.H. WilliamsD.L. Thioredoxin glutathione reductase: Its role in redox biology and potential as a target for drugs against neglected diseases Biochim. Biophys. Acta 2011 1810 1262 1271 10.1016/j.bbagen.2011.06.024321093421782895 Search in Google Scholar

[69] Ramanathan R.K., Stephenson J.J., Weiss G.J., Pestano L.A., Lowe A., Hiscox A., Leos R.A., Martin J.C., Kirkpatrick L., Richards D.A.: A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy. Invest. New Drugs, 2012; 30: 1591–1596 RamanathanR.K. StephensonJ.J. WeissG.J. PestanoL.A. LoweA. HiscoxA. LeosR.A. MartinJ.C. KirkpatrickL. RichardsD.A. A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy Invest. New Drugs 2012 30 1591 1596 10.1007/s10637-011-9739-921863237 Search in Google Scholar

[70] Raninga P.V., Di Trapani G., Vuckovic S., Bhatia M., Tonissen K.F.: Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma. Oncotarget, 2015; 6: 15410–15424 RaningaP.V. Di TrapaniG. VuckovicS. BhatiaM. TonissenK.F. Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma Oncotarget 2015 6 15410 15424 10.18632/oncotarget.3795455816025945832 Search in Google Scholar

[71] Ren X., Zou L., Lu J., Holmgren A.: Selenocysteine in mammalian thioredoxin reductase and application of ebselen as a therapeutic. Free Radic. Biol. Med., 2018; 127: 238–247 RenX. ZouL. LuJ. HolmgrenA. Selenocysteine in mammalian thioredoxin reductase and application of ebselen as a therapeutic Free Radic. Biol. Med. 2018 127 238 247 10.1016/j.freeradbiomed.2018.05.08129807162 Search in Google Scholar

[72] Ren X., Zou L., Zhang X., Branco V., Wang J., Carvalho C., Holmgren A., Lu J.: Redox signaling mediated by thioredoxin and glutathione systems in the central nervous system. Antioxid. Redox Signal., 2017; 27: 989–1010 RenX. ZouL. ZhangX. BrancoV. WangJ. CarvalhoC. HolmgrenA. LuJ. Redox signaling mediated by thioredoxin and glutathione systems in the central nervous system Antioxid. Redox Signal. 2017 27 989 1010 10.1089/ars.2016.6925564912628443683 Search in Google Scholar

[73] Rendón J.L., Miranda-Leyva M., Guevara-Flores A., Martínez-González J.J., Del Arenal I.P., Flores-Herrera O., Pardo J.P.: Insight into the mechanistic basis of the hysteretic-like kinetic behavior of thioredoxin-glutathione reductase (TGR). Enzyme Res., 2018; 2018: 3215462 RendónJ.L. Miranda-LeyvaM. Guevara-FloresA. Martínez-GonzálezJ.J. Del ArenalI.P. Flores-HerreraO. PardoJ.P. Insight into the mechanistic basis of the hysteretic-like kinetic behavior of thioredoxin-glutathione reductase (TGR) Enzyme Res. 2018 2018 3215462 10.1155/2018/3215462614515530254758 Search in Google Scholar

[74] Rhee S.G.: Overview on peroxiredoxin. Mol. Cells, 2016; 39: 1–5 RheeS.G. Overview on peroxiredoxin Mol. Cells 2016 39 1 5 10.14348/molcells.2016.2368474986826831451 Search in Google Scholar

[75] Rhee S.G., Woo H.A., Kil I.S., Bae S.H.: Peroxiredoxin functions as a peroxidase and a regulator and sensor of local peroxides. J. Biol. Chem., 2012; 287: 4403–4410 RheeS.G. WooH.A. KilI.S. BaeS.H. Peroxiredoxin functions as a peroxidase and a regulator and sensor of local peroxides J. Biol. Chem. 2012 287 4403 4410 10.1074/jbc.R111.283432328160722147704 Search in Google Scholar

[76] Rodriguez-Garcia A., Hevia D., Mayo J.C., Gonzalez-Menendez P., Coppo L., Lu J., Holmgren A., Sainz R.M.: Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells. Redox Biol., 2017; 12: 634–647 Rodriguez-GarciaA. HeviaD. MayoJ.C. Gonzalez-MenendezP. CoppoL. LuJ. HolmgrenA. SainzR.M. Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells Redox Biol. 2017 12 634 647 10.1016/j.redox.2017.03.025538562228391184 Search in Google Scholar

[77] Roos G., Foloppe N., Van Laer K., Wyns L., Nilsson L., Geerlings P., Messens J.: How thioredoxin dissociates its mixed disulfide. PLoS Comput. Biol., 2009; 5: e1000461 RoosG. FoloppeN. Van LaerK. WynsL. NilssonL. GeerlingsP. MessensJ. How thioredoxin dissociates its mixed disulfide PLoS Comput. Biol. 2009 5 e1000461 10.1371/journal.pcbi.1000461271418119675666 Search in Google Scholar

[78] Saccoccia, F., Angelucci F., Boumis G., Carotti D., Desiato G., Miele A.E., Bellelli A.: Thioredoxin reductase and its inhibitors. Curr. Protein Pept. Sci., 2014; 15, 621–646 SaccocciaF. AngelucciF. BoumisG. CarottiD. DesiatoG. MieleA.E. BellelliA. Thioredoxin reductase and its inhibitors Curr. Protein Pept. Sci. 2014 15 621 646 10.2174/1389203715666140530091910427583624875642 Search in Google Scholar

[79] Sandargo B., Thongbai B., Praditya D., Steinmann E., Stadler M., Surup F.: Antiviral 4-hydroxypleurogrisein and antimicrobial pleurotin derivatives from cultures of the nematophagous basidiomycete Hohenbuehelia grisea. Molecules, 2018; 23: 2697 SandargoB. ThongbaiB. PradityaD. SteinmannE. StadlerM. SurupF. Antiviral 4-hydroxypleurogrisein and antimicrobial pleurotin derivatives from cultures of the nematophagous basidiomycete Hohenbuehelia grisea Molecules 2018 23 2697 10.3390/molecules23102697622266030347707 Search in Google Scholar

[80] Sugiura Y., Araki K., Iemura S.I., Natsume T., Hoseki J., Nagata, K.: Novel thioredoxin-related transmembrane protein TMX4 has reductase activity. J. Biol. Chem., 2010; 285: 7135–7142 SugiuraY. ArakiK. IemuraS.I. NatsumeT. HosekiJ. NagataK. Novel thioredoxin-related transmembrane protein TMX4 has reductase activity J. Biol. Chem. 2010 285 7135 7142 10.1074/jbc.M109.082545284416320056998 Search in Google Scholar

[81] Sweeney M., Coyle R., Kavanagh P., Berezin A.A., Re D.L., Zissimou G.A., Koutentis P.A., Carty M.P., Aldabbagh F.: Discovery of anti-cancer activity for benzo [1,2,4] triazin-7-ones: Very strong correlation to pleurotin and thioredoxin reductase inhibition. Bioorg. Med. Chem., 2016; 24: 3565–3570 SweeneyM. CoyleR. KavanaghP. BerezinA.A. ReD.L. ZissimouG.A. KoutentisP.A. CartyM.P. AldabbaghF. Discovery of anti-cancer activity for benzo [1,2,4] triazin-7-ones: Very strong correlation to pleurotin and thioredoxin reductase inhibition Bioorg. Med. Chem. 2016 24 3565 3570 10.1016/j.bmc.2016.05.06627290691 Search in Google Scholar

[82] Tan S.X., Greetham D., Raeth S., Grant C.M., Dawes I.W., Perrone G.G.: The thioredoxin-thioredoxin reductase system can function in vivo as an alternative system to reduce oxidized glutathione in Saccharomyces cerevisiae. J. Biol. Chem., 2010; 285: 6118–6126 TanS.X. GreethamD. RaethS. GrantC.M. DawesI.W. PerroneG.G. The thioredoxin-thioredoxin reductase system can function in vivo as an alternative system to reduce oxidized glutathione in Saccharomyces cerevisiae J. Biol. Chem. 2010 285 6118 6126 10.1074/jbc.M109.062844282540619951944 Search in Google Scholar

[83] Toledano M.B., Delaunay-Moisan A., Outten C.E., Igbaria A.: Functions and cellular compartmentation of the thioredoxin and glutathione pathways in yeast. Antioxid. Redox Signal., 2013; 18: 1699–1711 ToledanoM.B. Delaunay-MoisanA. OuttenC.E. IgbariaA. Functions and cellular compartmentation of the thioredoxin and glutathione pathways in yeast Antioxid. Redox Signal. 2013 18 1699 1711 10.1089/ars.2012.5033377155023198979 Search in Google Scholar

[84] Tonissen K.F., Di Trapani G.: Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol. Nutr. Food Res., 2009; 53: 87–103 TonissenK.F. Di TrapaniG. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy Mol. Nutr. Food Res. 2009 53 87 103 10.1002/mnfr.20070049218979503 Search in Google Scholar

[85] Ukuwela A.A., Bush A.I., Wedd A.G., Xiao Z.: Glutaredoxins employ parallel monothiol-dithiol mechanisms to catalyze thioldisulfide exchanges with protein disulfides. Chem. Sci., 2018; 9: 1173–1183 UkuwelaA.A. BushA.I. WeddA.G. XiaoZ. Glutaredoxins employ parallel monothiol-dithiol mechanisms to catalyze thioldisulfide exchanges with protein disulfides Chem. Sci. 2018 9 1173 1183 10.1039/C7SC04416J588559329675162 Search in Google Scholar

[86] Vandervore L.V., Schot R., Milanese C., Smits D.J., Kasteleijn E., Fry A.E., Pilz D.T., Brock S., Börklü-Yücel E., Post M., Bahi-Buisson N., Sánchez-Soler M.J., van Slegtenhors M., Keren B., Afenjar A. i wsp.: TMX2 is a crucial regulator of cellular redox state, and its dysfunction causes severe brain developmental abnormalities. Am. J. Hum. Genet, 2019; 105: 1126–1147 VandervoreL.V. SchotR. MilaneseC. SmitsD.J. KasteleijnE. FryA.E. PilzD.T. BrockS. Börklü-YücelE. PostM. Bahi-BuissonN. Sánchez-SolerM.J. van SlegtenhorsM. KerenB. AfenjarA. TMX2 is a crucial regulator of cellular redox state, and its dysfunction causes severe brain developmental abnormalities Am. J. Hum. Genet 2019 105 1126 1147 10.1016/j.ajhg.2019.10.009690480431735293 Search in Google Scholar

[87] Watanabe R., Nakamura H., Masutani H., Yodoi J.: Anti-oxidative, anti-cancer and anti-inflammatory actions by thioredoxin 1 and thioredoxin-binding protein-2. Pharmacol. Ther., 2010; 127: 261–270 WatanabeR. NakamuraH. MasutaniH. YodoiJ. Anti-oxidative, anti-cancer and anti-inflammatory actions by thioredoxin 1 and thioredoxin-binding protein-2 Pharmacol. Ther. 2010 127 261 270 10.1016/j.pharmthera.2010.04.00420435060 Search in Google Scholar

[88] Wu C., Parrott A.M., Fu C., Liu T., Marino S.M., Gladyshev V.N., Jain M.R., Baykal A.T., Li Q., Oka S., Sadoshima J., Beuve A., Simmons W.J., Li H.: Thioredoxin 1-mediated post-translational modifications: Reduction, transnitrosylation, denitrosylation, and related proteomics methodologies. Antioxid. Redox Signal., 2011; 15: 2565–2604 WuC. ParrottA.M. FuC. LiuT. MarinoS.M. GladyshevV.N. JainM.R. BaykalA.T. LiQ. OkaS. SadoshimaJ. BeuveA. SimmonsW.J. LiH. Thioredoxin 1-mediated post-translational modifications: Reduction, transnitrosylation, denitrosylation, and related proteomics methodologies Antioxid. Redox Signal. 2011 15 2565 2604 10.1089/ars.2010.3831317634821453190 Search in Google Scholar

[89] Yoshioka J.: Thioredoxin superfamily and its effects on cardiac physiology and pathology. Compr. Physiol., 2011; 5: 513–530 YoshiokaJ. Thioredoxin superfamily and its effects on cardiac physiology and pathology Compr. Physiol. 2011 5 513 530 10.1002/cphy.c14004225880503 Search in Google Scholar

[90] Zeng H.H., Wang L.H.: Targeting thioredoxin reductase: Anticancer agents and chemopreventive compounds. Med. Chem., 2010; 6: 286–297 ZengH.H. WangL.H. Targeting thioredoxin reductase: Anticancer agents and chemopreventive compounds Med. Chem. 2010 6 286 297 10.2174/15734061079335886420977412 Search in Google Scholar

[91] Zhang J., Zhang B., Li X., Han X., Liu R., Fang J.: Small molecule inhibitors of mammalian thioredoxin reductase as potential anti-cancer agents: An update. Med. Res. Rev., 2019; 39: 5–39 ZhangJ. ZhangB. LiX. HanX. LiuR. FangJ. Small molecule inhibitors of mammalian thioredoxin reductase as potential anti-cancer agents: An update Med. Res. Rev. 2019 39 5 39 10.1002/med.2150729727025 Search in Google Scholar

[92] Zhang J.J., Muenzner J.K., Abu El Maaty M.A., Karge B., Schobert R., Wölfl S., Ott I.: A multi-target caffeine derived rhodium (I) N-heterocyclic carbene complex: Evaluation of the mechanism of action. Dalton Trans., 2016; 45: 13161–13168 ZhangJ.J. MuenznerJ.K. Abu El MaatyM.A. KargeB. SchobertR. WölflS. OttI. A multi-target caffeine derived rhodium (I) N-heterocyclic carbene complex: Evaluation of the mechanism of action Dalton Trans. 2016 45 13161 13168 10.1039/C6DT02025A27334935 Search in Google Scholar

[93] Zhu H., Tao X., Zhou L., Sheng B., Zhu X., Zhu X.: Expression of thioredoxin 1 and peroxiredoxins in squamous cervical carcinoma and its predictive role in NACT. BMC Cancer, 2019; 19: 865 ZhuH. TaoX. ZhouL. ShengB. ZhuX. ZhuX. Expression of thioredoxin 1 and peroxiredoxins in squamous cervical carcinoma and its predictive role in NACT BMC Cancer 2019 19 865 10.1186/s12885-019-6046-x671683831470801 Search in Google Scholar